Cucurbitacin IIbCAS# 50298-90-3 |
- Cucurbitacin P
Catalog No.:BCN0920
CAS No.:25383-26-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 50298-90-3 | SDF | Download SDF |
| PubChem ID | 72421 | Appearance | Powder |
| Formula | C30H48O7 | M.Wt | 520.70 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S,3S,8S,9R,10R,13R,14S,16R)-17-[(2R)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one | ||
| SMILES | CC1(C(C(CC2C1=CCC3C2(C(=O)CC4(C3(CC(C4C(C)(C(=O)CCC(C)(C)O)O)O)C)C)C)O)O)C | ||
| Standard InChIKey | VVBWBGOEAVGFTN-BLGDFNBKSA-N | ||
| Standard InChI | InChI=1S/C30H48O7/c1-25(2,36)12-11-21(33)30(8,37)23-19(32)14-27(5)20-10-9-16-17(13-18(31)24(35)26(16,3)4)29(20,7)22(34)15-28(23,27)6/h9,17-20,23-24,31-32,35-37H,10-15H2,1-8H3/t17-,18+,19-,20+,23?,24-,27+,28-,29+,30+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cucurbitacin IIb is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis. Cucurbitacin IIb exhibits its anti-inflammatory activity through modulating multiple cellular behaviors and signaling pathways, leading to the suppression of the adaptive immune response. Cucurbitacin IIb also can induce apoptosis of concanavalin A-activated mouse lymphocytes. |
| Targets | IFN-γ | IL Receptor | p38MAPK | JNK | ERK | NF-kB | IkB | TNF-α | p65 | STAT | IKK |
| In vitro | Cucurbitacin IIb exhibits anti-inflammatory activity through modulating multiple cellular behaviors of mouse lymphocytes.[Pubmed: 24587010]PLoS One. 2014 Feb 25;9(2):e89751.Cucurbitacin IIb (CuIIb) is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis. However, its action mechanism has not been completely understood. This study aimed to explore the anti-inflammatory activity of Cucurbitacin IIb and its underlying mechanism in mitogen-activated lymphocytes isolated from mouse mesenteric lymph nodes. |
Cucurbitacin IIb Dilution Calculator
Cucurbitacin IIb Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9205 mL | 9.6025 mL | 19.2049 mL | 38.4098 mL | 48.0123 mL |
| 5 mM | 0.3841 mL | 1.9205 mL | 3.841 mL | 7.682 mL | 9.6025 mL |
| 10 mM | 0.192 mL | 0.9602 mL | 1.9205 mL | 3.841 mL | 4.8012 mL |
| 50 mM | 0.0384 mL | 0.192 mL | 0.3841 mL | 0.7682 mL | 0.9602 mL |
| 100 mM | 0.0192 mL | 0.096 mL | 0.192 mL | 0.3841 mL | 0.4801 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Erythrocentaurin
Catalog No.:BCN7684
CAS No.:50276-98-7
- Oleuropeic acid
Catalog No.:BCN5611
CAS No.:5027-76-9
- Phloracetophenone 4'-O-glucoside
Catalog No.:BCN4052
CAS No.:5027-30-5
- Lonidamine
Catalog No.:BCC9012
CAS No.:50264-69-2
- SQ109
Catalog No.:BCC1962
CAS No.:502487-67-4
- NIDA 41020
Catalog No.:BCC7810
CAS No.:502486-89-7
- H-Trp-NH2.HCl
Catalog No.:BCC3112
CAS No.:5022-65-1
- HLI 373
Catalog No.:BCC2408
CAS No.:502137-98-6
- Cyclopentadecanone
Catalog No.:BCN3822
CAS No.:502-72-7
- Phytone
Catalog No.:BCN4628
CAS No.:502-69-2
- Lycopene
Catalog No.:BCN5410
CAS No.:502-65-8
- SB705498
Catalog No.:BCC3854
CAS No.:501951-42-4
- Boc-His(Z)-OH
Catalog No.:BCC3404
CAS No.:50305-43-6
- Vilanterol
Catalog No.:BCC4030
CAS No.:503068-34-6
- Vilanterol trifenatate
Catalog No.:BCC4031
CAS No.:503070-58-4
- N-Methylflindersine
Catalog No.:BCN3641
CAS No.:50333-13-6
- 3'-Galloylquercitrin
Catalog No.:BCN8254
CAS No.:503446-90-0
- NU7441 (KU-57788)
Catalog No.:BCC3679
CAS No.:503468-95-9
- glucagon receptor antagonists 1
Catalog No.:BCC1593
CAS No.:503559-84-0
- Pentamidine dihydrochloride
Catalog No.:BCC5194
CAS No.:50357-45-4
- Apixaban
Catalog No.:BCC2295
CAS No.:503612-47-3
- Cyclo(Phe-Gly)
Catalog No.:BCN2431
CAS No.:5037-75-2
- (-)-di-de-Omethylgrandisin
Catalog No.:BCN7872
CAS No.:50393-98-1
- Orcinol
Catalog No.:BCN5612
CAS No.:504-15-4
Cucurbitacin IIb exhibits anti-inflammatory activity through modulating multiple cellular behaviors of mouse lymphocytes.[Pubmed:24587010]
PLoS One. 2014 Feb 25;9(2):e89751.
Cucurbitacin IIb (CuIIb) is one of the major active compounds in Hemsleyadine tablets which have been used for clinical treatment of bacillary dysentery, enteritis and acute tonsilitis. However, its action mechanism has not been completely understood. This study aimed to explore the anti-inflammatory activity of CuIIb and its underlying mechanism in mitogen-activated lymphocytes isolated from mouse mesenteric lymph nodes. The results showed that CuIIb inhibited the proliferation of concanavalin A (Con A)-activated lymphocytes in a time- and dose-dependent manner. CuIIb treatment arrested their cell cycle in S and G2/M phases probably due to the disruption of the actin cytoskeleton and the modulation of p27(Kip1) and cyclin levels. Moreover, the surface expression of activation markers CD69 and CD25 on Con A-activated CD3(+) T lymphocytes was suppressed by CuIIb treatment. Both Con A- and phorbol ester plus ionomycin-induced expression of TNF-alpha, IFN-gamma and IL-6 proteins was attenuated upon exposure to CuIIb. Mechanistically, CuIIb treatment suppressed the phosphorylation of JNK and Erk1/2 but not p38 in Con A-activated lymphocytes. Although CuIIb unexpectedly enhanced the phosphorylation of IkappaB and NF-kappaB (p65), it blocked the nuclear translocation of NF-kappaB (p65). In support of this, CuIIb significantly decreased the mRNA levels of IkappaBalpha and TNF-alpha, two target genes of NF-kappaB, in Con A-activated lymphocytes. In addition, CuIIb downregulated Con A-induced STAT3 phosphorylation and increased cell apoptosis. Collectively, these results suggest that CuIIb exhibits its anti-inflammatory activity through modulating multiple cellular behaviors and signaling pathways, leading to the suppression of the adaptive immune response.
